Phibro Animal Health Corporation (NASDAQ:PAHC) Receives Consensus Rating of “Hold” from Analysts

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) have been given an average rating of “Hold” by the eight ratings firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $31.40.

Several equities research analysts have recently commented on the company. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Monday. JPMorgan Chase & Co. boosted their price target on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Bank of America upped their price target on Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a research report on Friday, August 29th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Tuesday. Finally, Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a research note on Thursday, August 28th.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 38,303 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $45.29, for a total value of $1,734,742.87. Following the completion of the transaction, the chief executive officer owned 20,577 shares of the company’s stock, valued at approximately $931,932.33. This represents a 65.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 109,159 shares of company stock worth $4,620,198. 50.13% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Phibro Animal Health

Several large investors have recently made changes to their positions in the business. Nuveen LLC purchased a new stake in shares of Phibro Animal Health during the first quarter worth about $10,312,000. Capricorn Fund Managers Ltd bought a new position in Phibro Animal Health in the 3rd quarter worth approximately $10,233,000. JPMorgan Chase & Co. grew its holdings in Phibro Animal Health by 1,730.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after buying an additional 225,110 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in Phibro Animal Health during the 3rd quarter valued at approximately $8,931,000. Finally, Invesco Ltd. raised its position in shares of Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock valued at $8,282,000 after buying an additional 186,087 shares during the last quarter. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Phibro Animal Health Trading Down 0.0%

Phibro Animal Health stock opened at $45.32 on Thursday. Phibro Animal Health has a 52-week low of $16.16 and a 52-week high of $46.42. The company has a market cap of $1.84 billion, a P/E ratio of 38.41, a P/E/G ratio of 1.24 and a beta of 0.81. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46. The business has a 50-day simple moving average of $40.20 and a two-hundred day simple moving average of $31.53.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The company had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Analysts predict that Phibro Animal Health will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th will be paid a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.1%. Phibro Animal Health’s dividend payout ratio is 28.92%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.